PhRMA Advises Members To Respect Independence Of Patient Organizations
This article was originally published in The Pink Sheet Daily
Executive Summary
Association’s principles on interactions with patient organizations says no company should require that it be the sole funder of a group.
You may also be interested in...
Patient Advocacy 3.0: Outreach Stretches to First Stages of Regulatory Development
FDA is ready to bring patient voices and perspectives into the drug approval framework. Practically, that means that drug sponsors will have to develop new skills and structures for working with a familiar stakeholder group at an unfamiliar point in the drug development process. The new challenge was a major theme at PhRMA’s 2012 Annual Meeting.
Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation
Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
Innovative Trial Designs Are 'Life And Death Matter' For Pharma, Amgen Tells US FDA
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: